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L o w -D o s e  M eth otrexate  in Patients W ith A d van ced  or 
M e ta s ta t ic  C olorecta l Cancer: F inal R esu lts  o f  a 
R a n d o m iz e d  E uropean  O rganization  for R esearch  and
T reatm en t of Cancer Study
By Geerf Blijham, Theo Wagener, Jacques Wils, Jacques de Greve, Marc Buset, Harry Bleiberg, Angel Lacave,
Mats Dalmark, Jean Selleslag, Laurence Collette, and Tarek Sahmoud
Purpose: Methotrexate (MTX) has been described to 
modulate the activity of fluorouracil (5-FU) in patients with 
metastatic colorectal cancer. The European Organization 
for Research and Treatment of Cancer (EORTC) Gastrointes­
tinal Tract Cancer Cooperative Group (GITCCG) conducted 
a phase III trial to investigate the efficacy and tolarability 
of the addition of low-dose MTX (40 mg/m2) to high-dose 
infusional 5-FU (60 mg/kg over 48 hours) given weekly for
4 weeks and thereafter every 2 (for 4 weeks) and 3 weeks.
Patients and Methods: Three hundred ten patients 
were randomized between 1987 and 1992. Eligible pa­
tients had measurable advanced or metastatic colorectal 
cancer and had not been pretreated with antifolates or 
fluorodinated pyrimidines. All 297 eligible patients were 
evaluated for survival; toxicity was assessed in 292 pa­
tients who received at least one course of treatment* Pa­
tients with bidimensionally measurable disease (n = 230)
ONE OF THE FIRST drugs found to modulate the cytotoxic activity of fluorouracil (5-FU) was 
methotrexate (MTX),1 This drug inhibits dihydrofolate 
reductase, which leads to inhibition of purine synthesis 
and thereby increased levels of the phosphate donor 
phosphoribosylphosphate (PRPP). As a consequence, 
the intracellular formation of 5-FU nucleotides is en­
hanced, with increased incorporation of 5-FU into RNA 
and increased levels of fiuorodeoxyuridine monophos­
phate (FclUMP), the inhibitor of thymidylate synthe­
tase.2
In a number of in vivo and in vitro tumor models, 
MTX, if given before 5-FU, was indeed found to enhance 
5-FU-induced cytotoxicity.3 Subsequent phase II trials 
in patients with metastatic colorectal cancer were summa­
rized by Kemeny et al4 and Hermann et al,3 who showed
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were also evaluated for response according to standard 
criteria.
Results: The addition of low-dose MTX to high-dose in­
fusional 5-FU led to a doubling of the response rate from 
10% to 21% (P = .025). The median survival time also in­
creased from 9.3 to 12.5 months, but this difference was 
not statistically significant {P = .12). High-dose infusional 
5-FU with or without low-dose MTX was well tolerated, 
with grade 3 to 4 toxicity in greater than 10% of patients 
only occurring for stomatitis with the combination treat­
ment. Performance status was the sole prognostic factor for 
survival in a multivariate analysis.
Conclusion: Low-dose MTX effectively modulated high- 
dose infusional 5-FU in a large, randomized trial in which 
less than 5% of patients received leucovorin.
J Clin Oncol 14:2266-2273. © 1996 by American So­
ciety o f Clinical Oncology.
that response rates of approximately 35% could be ob­
tained with MTX doses as low as 40 mg/m2 if MTX 
preceded 5-FU administration by at least 3 hours.
In 1986, the European Organization for Research and 
Treatment of Cancer (EORTC) Gastrointestinal Tract 
Cancer Cooperative Group (GITCCG) decided to test the 
concept of modulation by MTX in a phase III trial. The 
trial was designed according to the principle to make the 
dose-intensity of the active drug (5-FU) as high as possi­
ble and that of the modulating drug (MTX) as low as 
possible.6 This would allow the best testing of biochemi­
cal modulation without the inherent tendency of the mod­
ulating drug to compromise the dose-intensity of 5-FU. 
Kemeny et al4 used 40 mg/m2 of MTX followed 24 hours 
later by 600 mg/m2 of 5-FU and found a response rate 
of 32%. Moreover, this dose of MTX could be given 
without leucovorin rescue, which made it unnecessary to 
introduce the bias of this, possibly, also modulating 
agent.7 Therefore, this dose of MTX was chosen for mod­
ulation.
Investigators from Vancouver8 pioneered a number of 
ways to administer 5-FU in continuous infusions of short 
duration but at frequent intervals. The best results (30% 
response rate) were obtained with 48-hour infusions of 
60 mg/kg 5-FU given weekly. This approximates a dose­
intensi ty of approximately 2.5 mg/m2/wk, which is con­
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siderably higher than with any other schedule and close 
to the maximal-tolerated dose of 5-FU 3.0g/m2/wk).(i,1° 
Based on these rationales and after a pilot study of this 
particular combination of low-dose MTX and high-dose 
5-FU was performed, the phase III study was started in 
1987. Interim data have been reported at several meetings; 
this is the final report.
PATIENTS AND METHODS
Eligibility Criteria
Patients were eligible if they had advanced unresectable or meta­
static adenocarcinoma of the colon or rectum. The presence of ade­
nocarcinoma had to be histologically or cytologically documented, 
preferably on a metastatic lesion or, if this was impossible, on the 
primary tumor. In the latter situation, unequivocal clinical evidence 
of a progressive lesion was required. Patients had measurable or 
assessable disease that included lung metastases measurable in one 
or two dimensions on x-ray, palpable nodules and nodes, hepatomeg­
aly if the inferior liver edge was palpated at 5 cm below the cortal 
margin, and lesions visible on computed tomographic-scan or ultra­
sound that could be measured in at least one diameter. Lesions in 
irradiated fields, effusions, bone metastases, malignant ulcers, and 
changes in biochemical tests, including tumor marker levels, were 
not considered measurable or assessable manifestations of disease. 
Patients were less than 71 years of age; had a World Health Organi­
zation (WHO) performance status of 0 , 1, or 2; and had adequate 
liver (bilirubin level <  50 ¿zmol/L), kidney (creatinine concentration 
<  120 jumol/L), and hematologic (WBC count >  3,000//iL and 
platelet count >  I00,000//uL) function. Patients with a life expec­
tancy shorter than 3 months, previous chemotherapy with fluonodi- 
nated pyrimidines or folate antagonists, uncontrolled cardiac disease, 
CNS metastases, active infection, or a history of other malignant 
disease except nonmelanoma skin cancer or treated carcinoma-in- 
situ of the uterine cervix were excluded. Patients using salicylates 
or other nonsteroidal antiinflammatory agents were only eligible if 
the medications could be discontinued during treatment. Patients 
with pleural or peritoneal effusions could only be entered if these 
effusions were controlled to very small volumes before therapy 
started.
Randomization
Patients were randomized by telephone call or through the Euro- 
Code Network, at the EORTC Data Center in Brussels, Belgium. 
Patients were stratified by institution. They were randomized to re­
ceive one of the following regimens: (!) high-dose infusional 5-FU
4
or (2) the same 5-FU treatment plus low-dose bolus MTX.
Chemotherapy
5-FU treatment consisted of a continuous infusion of 60 mg/kg 
over 48 hours in 5% glucose or dextrose. The drug could be given 
through a peripheral line or through a central line, mostly in connec­
tion with a fully implantable port system. In some institutions, pa­
tients were admitted for this treatment, but in most cases, 5-FU was 
given through a central line connected to an ambulatory pump. Four 
courses were given at weekly intervals, and another four at 2 -week 
intervals. In case of stable or responding disease, treatment was
continued on an every-3-week basis until progression or unaccept­
able toxicity. According to randomization, half of the patients also 
received MTX 40 mg/m2 by intravenous push just before the start 
of each 5-FU infusion. Doses and schedules of 5-FU were identical 
to those in the other arm.
Dose Modifications
In case of a WBC count less than 3,000//iL, or stomatitis grade
1 or diarrhea grade 1 on the day before the start of infusion, treatment 
was delayed for 1 week and restarted if the patient had recovered 
at the same doses. In case of stomatitis greater than grade 1 or 
diarrhea greater than grade 1, treatment was delayed for 1 week and 
restarted at 75% of the 5-FU dose with leucovorin rescue 22.5 mg 
orally every 6 hours for eight doses starting 24 hours after MTX. 
Treatment was withheld if the serum creatinine concentration in­
creased to greater than 120 /jmol/L. Patients with a more than 1 week 
delay of treatment were taken off protocol. In case of retrosternal 
discomfort, ECG and cardiac enzymes were obtained. If abnormal, 
treatment was discontinued; if normal, the next course was given 
with monitoring of ECG and cardiac enzymes.
Disease and Treatment Evaluation
Complete response was defined in the disappearance of all known 
disease determined by two observations at least 4 weeks apart. Partial 
response required a decrease by 2= 50% in the sum of the product 
of the largest perpendicular diameLers of all bidimensionally measur­
able indicator lesions. It was not neccxsary for all lesions to have 
regressed to qualify for a partial response, but no lesions should 
have progressed and no new lesions should have appeared. Disease 
progression was defined as a ^  25% increase in the size of at 
least one measurable lesion or the appearance of a new lesion. The 
occurrence of effusions was considered progression if the cytology 
was positive. Patients who did not qualify for response or progression 
were considered stable. Patients were assessable for response pro­
vided they had received 12  weeks of therapy or had been taken off 
protocol because of progressive disease before that time. In the latter 
situation, they were classified as having early progression. Patients 
were assessable for toxicity provided they had received at least one 
course of therapy. In a few instances, patients were declared not 
assessable for efficacy or toxicity because of severe protocol viola­
tions as decided by the study coordinator. Partial and complete re­
sponses were evaluated extramurally.
St a tistica I Con side rations
Randomization was centralized in the EORTC Data Center. Dur­
ing randomization, patients were stratified by institution. The ran­
domization was performed using the minimization technique.11 As­
suming that the 1 -year survival rate in the 5-FU arm is approximately 
30%, a total of 308 patients (154 in each treatment arm) was neces­
sary to detect an increase to 45% in the 5-FU-MTX arm with a two- 
sided type I error of 0.05 and a power of 80% .'2 Response rales 
were compared using the x 2 test for all patienLs who had a least one 
bidimensionally measurable lesion at entry. Duration of response 
was calculated from the date of progression. Survival curves were 
estimated using the Kaplan-Meier technique.1*1 Differences in the 
duration of survival were compared using a two-sided log-rank test.14 
To adjust for confounding variables, the Cox proportional hazards 
model15 was used. Except for survival, which was based on all
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Table 1. Eligibility and Assessabrlity of Patients
No. of Patients
Variable High-Dose 5-FU
Low-Dose MIX/ 
High-Dose 5-FU
Randomized 156 154
Eligible
Assessable For
151 146
Toxicity 148 Ì44
Response 116 114
Survival 156 153
randomized patients for whom any information was received after 
being randomized (all patients but one), all other analyses were 
based on all eligible and assessable patients.
Administrative Data
Between 1987 and 1992 310 patients were registered (Table 1). 
Thirteen (4%) were ineligible becausc of the absence of measurable 
or assessable disease (n -  7), incomplete or inadequate data (n ~ 
4), or poor physical condition (n =  2). Five eligible patients were 
not assessable for toxicity because treatment was never started (n = 
4) or lack of data (n = 1). Bidimensionally measurable lesions were 
present in 230 patients, who were therefore assessable for response. 
Survival data were available on all patients but one.
RESULTS
Patient Characteristics
Table 2 lists patient characteristics at entry per treat­
ment arm. Seventy-six percent of patients were aged 
greater than 50 years; 67% had a rectosigmoid primary 
tumor site. Seventy-seven percent of patients had bidi­
mensionally measurable disease at randomization. The 
large majority (89%) of patients had received surgery 
(curative or palliative) and only nine patients (3%) had 
received prior chemotherapy, mainly in the context of a 
phase II study with an experimental agent that was not 
an antifolate or fluoridinated pyrimidine.
Tumor Response
In six patients in the high-dose 5-FU arm and eight 
patients in the low-dose MTX/high-dose 5-FU arm, re­
sponse could not be assessed due to premature discontinu­
ation of treatment (n = 10), major protocol violations (n 
= 2), or lack of data (n = 2). Table 3 lists tumor responses 
according to treatment in the remaining 216 patients with 
bidimensionally measurable disease. The response rate of 
low-dose MTX/high-dose 5-FU was superior to high-dose 
5-FU (23% v 11%; P  = .025). Similar results were ob­
tained when the 14 patients who were not assessable for 
response were included in the analysis.
Table 2, Patient and Tumor Characteristics at Entry by Treatment
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Group
Characteristic
High-Dose 5-FU 
In = 156)
low-Dose MTX/ 
High-Dose 5-FU 
(n = 154)
No. % No. %
Age, years
Median 57 59
Range 26-75 51-74
< 50 39 26 31 21
50-65 72 48 82 56
> 65 40 27 33 23
5 ex
Male 90 60 77 53
Weight loss (%)
None 01 40 52 36
1-10 47 31 44 30
> 10 19 13 18 12
Performance status
0 05 43 55 38
1 75 50 72 49
2 11 7 19 13
Site of primary tumor
Ascending 24 16 27 19
Transverse 11 7 16 11
Descending 5 3 8 6
Rectosigmoid 108 72 91 62
Prior surgery
None 13 9 15 10
Curative 61 40 78 53
Palliative 74 49 52 36
Prior radiotherapy 30 20 24 16
Prior chemotherapy 4 3 5 3
Sites of tumor*
Primary 16 11 19 13
Regional 53 34 44 29
Liver 105 67 105 68
Lung 29 19 22 14
*Some patients had > 1 site.
Table 3. Overall Response by Treatment Group
Response
Hlgh-Dose 5-FU 
(n = 110}
Low-Dose MTX/ 
High-Dose 5-FU 
(n = 106)
No, % No. %
Complete response 2 2 2 2
Partial response 10 9 22 21*
No change 38 35 39 37
Progression 42 38 27 26
Early progression 17 16 12 11
Early death
Malignant disease 1 1 2 2
Other 2 2
*Response rates are significantly different (P = .025).
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Fig 1. Survival by treatment 
group.
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Survival comparisons have been performed on the basis 
of all randomized patients following an intent-to-treat pol­
icy. With 293 of 309 patients dead, the median survival 
time was 9.3 months for the high-dose 5-FU arm and 
12.5 months for the low-dose MTX/high-dose 5-FU arm 
(Fig 1). This difference of 3 months is not statistically 
significant.
Adjustment for Prognostic Factors
A number of factors were analyzed for their impact on 
prognosis. Results from the univariate analysis are listed 
in Table 4. Only good performance status and prior sur­
gery (in particular, curative surgery) were associated with 
a favorable prognosis. Multivariate analysis was applied 
to adjust for possible prognostic factors. Only perfor­
mance status was retained in the model; patients with a 
performance status of 1 or 2 had a relative risk of 1.92 
compared with those with a performance status of 0 (P 
< .001). Treatment was not a significant prognostic factor 
when adjusting for performance status (P  = .19).
Toxicity
Side effects and toxicity for patients who received at 
least one cycle of treatment are listed in Table 5. Few
patients suffered hematologic side effects. Four patients 
in each treatment arm had cardiac toxicity that consisted 
of angina pectoris in five, an episode of high blood pres­
sure in one, and ECG changes in two. All symptoms were 
reversible. Four patients had cerebellar ataxia, of which 
one was grade 3 to 4. This occurred during early cycles 
(no. 1 to 5) and disappeared thereafter. A significant dif­
ference in favor of the high-dose 5-FU arm was observed 
for nausea and vomiting; however, even in the low-dose 
MTX/high-dose 5-FU arm, 45% of patients had no symp­
toms in this respect. The only other significant difference 
was the occurrence of stomatitis, which was virtually 
absent (10% grade I to 2) without but relatively frequent 
(43% grade 1 to 3) with MTX, This indicates that 40 mg/ 
m2/wk of methotrexate is close to the maximum dose that 
can be given in conjunction with high-dose 5-FU without 
the need for leucovorin rescue.
DISCUSSION
In this study, we found evidence for an enhancement 
of the treatment results of high-dose infusional 5-FU by 
the addition of low-dose MTX in patients with advanced 
inoperable or metastatic colorectal cancer. This enhance­
ment was moderate in size and consisted of a doubling 
of the percentage of responding patients (11% v 23%; P
2270
Table 4. Duration of Survival Comparisons According to Possible Prognostic Factors
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Prognostic Faclor O/N
Median Survival 
(months)
Relative
Risk
95%
Confidence
Interval P
Age, years
< 58 143/148 12.5 1.0
> 58 139/149 10.0 1.02 0.81-1.30 .842
Sex
Male 156/167 11.1 1.0
Female 126/130 11.7 0.95 0.75-1.20 .690
Weight loss (%)
< 10 192/204 12.1 1.0
> 10 90/93 8.8 1.09 0,84-1.40 .534
Performance status
0 112/122 14.2 1.0
1-2 166/171 7.8 1.92 1.50-2.45 <.001
Primary tumor site
Colon 86/91 8.1 1.0
Rectosigmoid 190/200 12.2 0.84 0.65-1.10 .204
Prior surgery
None 28/28 6.9 1.0 .038
Curative 131/139 13.2 0.6
Noncurative 119/126 9.7 0.7
None 28/28 6.9 1.0
Any surgery 250/265 11.9 0.6 0.39-0.98 .041
Prior radiotherapy
No 227/239 11.4 1.0
Yes 51/54 10.4 1.15 0.85-1.59 .382
Abbreviation: O /N , observed/number of patients.
=  .025) and a difference in the median survival time of 
3 months (P  = .12). These data show that a dose of MTX 
as low as 40 mg/m2 can modulate the activity of high- 
dose infusional 5-FU.
The Advanced Colorectal Cancer Meta-Analysis Proj­
ect16 identified seven other randomized trials that com­
pared 5-FU alone with 5-FU plus MTX, and included 
another 868 patients.7,17'22 In three of these trials,17,20,21 
the response rate was significantly higher in the 5-FU/ 
MTX arm; in no trial was the opposite true. The overall 
odds ratio for response was 0.51 (95% confidence inter­
val, 0.37 to 0.70) for all trials, including EORTC 40872, 
which indicates a highly significant advantage for 5-FU/ 
MTX (P < 10~4). For overall survival, only one study17 
showed a significant advantage for 5-FU/MTX, but sev­
eral. other trials showed survival trends leading to an over­
all survival odds rate of 0.87 (95% confidence interval,
0.77 to 0.98; P  = .024). These results did not change if 
prognostic information from a Cox regression model was 
taken into account.
Two of the modulations of 5-FU that have shown con­
siderable in vitro activity have now been found to modu­
late 5-FU efficacy in patients as well.14,23 The magnitude 
of the effects observed for leucovorin and MTX are about 
of similar size, with a doubling of the response rate (from
10% to ^  20%) and a nonsignificant (leucovorin) or 
small but significant (MTX) prolongation of survival. Di­
rect comparisons between leucovorin- and MTX-modu- 
lated 5-FU treatment have been performed by the North 
Central Cancer Treatment Group (NCCTG) (5-FU/MTX 
v 5-FU/leucovorin in two doses24), by three groups in­
cluded in the meta-analysis (5-FU v 5-FU/leucovorin v 5- 
FU/MTX),7,19,22 and by the Nordic Gastrointestinal Tumor 
Adjuvant Therapy Group.25 No differences in response 
rates were observed, with the exception that the extended 
NCCTG study found 5-FU/MTX (13% response rate) to 
be inferior to the other two arms (31% and 42% response 
rates). It should be noted, however, that only in that trial 
was the dose of 5-FU lower in the 5-FU/MTX group 
as compared to with 5-FU/leucovorin arms. It can be 
concluded that MTX and leucovorin are equally effective 
modulators of 5-FU in patients with metastatic colorectal 
cancer.
Our trial allowed the use of leucovorin in selected patients
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with MTX-induced toxicity. In actual practice, less than 5% 
of the patients in the low-dose MTX/high-dose 5-FU arm 
received leucovorin, realizing one of the important goals of 
choosing a low dose of MTX. In some other trials included 
in the meta-analysis that used higher doses of MTX (> 200 
mg/m2), leuco voiin rescue was routinely given, mostly after 
the administration of 5-FU and in low doses. Some contribu­
tion of leucovorin to the results obtained with MTX/5-FU 
combinations in these studies cannot be excluded. However, 
the results of the EORTC provide strong evidence that MTX 
is also a clinically effective modulator without the addition 
of leucovorin.
If MTX and leucovorin each modulate 5-FU activity, 
but through different mechanisms, would it be useful to 
combine both agents to obtain double modulation? We 
performed a phase II study of high-dose infusional 5-FU 
combined with oral leucovorin during 5-FU infusion in a 
dose that should allow for leucovorin levels greater than
1 ¿¿mol/L.26,27 A response rate of 25% was obtained. Re­
sults from experimental models have suggested that three- 
drug combinations of 5-FU, MTX, and leucovorin are not 
superior to two-drug combinations or may even be antago­
nistic.28'30 One reason may be that MTX and leucovorin 
compete for the same reduced folate transport mechanism 
to enter the cell.31 Trimetrexate, an MTX analog, can enter 
the cell by simple diffusion and may be more suitable for 
combination with leucovorin.31-34 A phase I trial with this 
combination in patients with metastatic colorectal cancer 
has been performed with promising results.35
The timing of the MTX administration is crucial for an 
optimal modulating effect in vitro.3 PRPP levels, thought 
to be the mean mediator of modulation, increase until a 
maximum after 24 hours. In clinical practice, intervals be­
tween MTX and bolus 5-FU greater than 3 to 4 hours have 
been found to be superior to shorter intervals.4,5 Marsh et 
al36 directly compared MTX 200 mg/m2 followed by 5-FU 
600 mg/m2 after 1 or 24 hours with leucovorin rescue 24 
hours after MTX. With the 24-hour interval, response rate 
(29% v 14%) and median survival time (15.3 v 11.4 months) 
were clearly superior. In our trial, 48-hour continuous infu­
sion rather than bolus 5-FU was applied. It was reasoned 
that with MTX given 24 hours before the start of 5-FU, 
PRPP levels would be the highest during the build up of 
5-FU levels and probably be declining or normal again 
during most of the 5-FU administration. With MTX given 
at the start of the infusion of 5-FU, maximum PRPP levels 
can be expected in the middle of the infusion. Therefore, 
the scheduling of our trial is not contradictory to but in line 
with what is known from experimental and clinical data 
regarding the optimal interval.
Table 5. Toxicity by Treatment Group According to WHO Criteria
Toxicity/Grade
Hïgh-Dose 5-FU 
In = 148)
LoW'Dose MTX/ 
Higb-Dose 5-FU 
(n = 144)
No. % No. %
Leukopenia
1-2 0 0
Thrombocytopenia
1-2 3 2 4 3
3-4 0 3 2
Renal
1-2 2 2 4 3
Hepatic
1-2 4 3 6 4
Nausea and vomiting*
1-2 52 35 69 48
3 5 3 10 7
Diarrhea
1 -2 36 24 46 32
3 2 1 4 3
Stomatitis f
1-2 15 10 48 33
3-4 2 1 14 10
Cutaneous
1 ~2 11 7 15 10
Alopecia
1-2 13 9 20 14
3 0 1 1
Cardiac
1-2 4 2 4 3
Ataxia
1-2 1 1 3 3
3-4 0 1 1
*P = .03.
+P= < .001.
The combination of low-dose MTX and high-dose infu- 
sional 5-FU was well tolerated. Myelosuppression was 
negligible and the most prominent toxicity was stomatitis, 
which occurred in 43% of patients and was severe (grade 
3 to 4) in 10%. This compares favorably with the inci­
dence of severe diarrhea and myelosuppression reported 
for weekly bolus 5-FU with high-dose leucovorin and 5- 
day bolus 5-FU with low-dose leucovorin.37 The avail­
ability of central lines with a subcutaneous reservoir and 
reliable pumps has increasingly allowed treatment to be 
given entirely at home. As a consequence, in the newer 
EORTC studies, the 3-week interval with later courses 
has been changed to a 2-week interval and the period 
of weekly administrations has been lengthened without 
detrimental effects as far as toxicity is concerned. Pro­
vided appropriate infusional technology is available, 
high-dose infusional 5-FU is an attractive treatment that 
can be modulated by low-dose MTX.
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